西格玛医学官方网站
  • 首页
  • 解决方案
    器械临床试验 注册人制度 医学监查 质量管理体系 注册服务 法规事务 器械SMO 第三方稽查 数据管理 生物统计 国际注册
  • 医械资源
    法律法规 指导原则 标准体系 行业规范 知识问答
  • 新闻资讯
    公司动态 行业资讯 媒体报道 西格洞察
  • 关于我们
    公司简介 公司荣誉 公司文化 公司优势
  • 联系我们
    加入我们 商务合作
|
首页 > 新闻资讯 > 行业资讯

Announcement of the National Medical Products Administrationon Matters Concerning Further Adjusting and Optimizing theProduction of Imported Medical Devices by Enterprises in China (N0.30, 2025)

作者:小编 更新时间:2025-04-02 点击数:

Announcement of the National Medical Products Administrationon Matters Concerning Further Adjusting and Optimizing theProduction of Imported Medical Devices by Enterprises in China(N0.30, 2025)


In September 2020, the Announcement of the National Medical Products Administration on MattersConcerning the Production of Imported Medical Devices by Enterprises in China (No.104, 2020hereinafter referred to as the Announcement) was issued and implemented. To thoroughly carry out thedeployment made by the Central Committee of the Communist Party of China and the State Council toadvance high-level opening to the outside world, fully implemnt the requirements of the Opinions oftheGeneral Ofice ofthe State Council on Comprehensively Deepening the Regulatory Reform ofDrugs andMedical Devices to Promote the High-guality Development ofthe Pharmaceutical industry (GBF [2024No.53), continuously deepen the regulatory refonm of medical devices, and promote the high-qualitydevelopment of the medical device industry, some requirements of the Announcement are further adjustedand optimized as follows:


I. Scope ofApplication


The foreign-invested enterprises mentioned in the Anmouncement may be an enterprise established bythe registrant of imported medical devices, or an enterprise with the same actual controller as the registrantof imported medical devices. That is, the Announcement applies to matters related to the production ofClass ll and Class lll products that have obta

ined registration certificates for imported medical deviceswithin the territory of the People's Republic of China by foreign-invested enterprises established byregistrants of imported medical devices or with the same actual controller.


The actual controller shall comply with the relevant definitions and provisions stipulated in theCompany Law ofthe People's Republic of'China, that is, the actual controller refers to the person who canpractically dominate the behaviors of a company through an investment relationship, agreement, or otherarrangements.


II. Requirements for Registration Application


(l)The registration applicant shall submit the registration application dossiers in accordanee with theformats and contents required in the Announcement of National Medical Products Administration onIssuing the Requirements for the Registration Application Dossiers and the Format ofApproval Certificatesof Medical Devices (No.121, 2021)and Announcement of National Medical Products Administration onIssuing the Requirements for Registration Application Dossiers ofIn Vitro Diagnostic Reagents andFormats efApproval Documents (No.122, 2021).


Among them, the overview data, non-clinical data (except the list of basic principles of safety andperfommance, produet technical requirements and inspection reports), and clinical evaluation data of theproduct can be the original registration application dossiers of imported medical devices. Product technicarequirements and inspection reports shall reflect that the product meets the applicable mandatory standard requriments.


(ll) If the registration applicant and the registrant of imported medical devices have the same actualcontroller, the explanatory and supporting documents that both parties have the same actual controller shalbe provided. The explanatory documents may contain the explanation of the equity relationship betweenthe two parties, etc., and the supporting documents shall include the reports containing information on theactual controller, such as the registration applicant's Anual Report of the Enterprise which is the mostrecent from the date of application for registration and have been uploaded or disclosed in accordance withthe requirements of the competent authorities. The corresponding explanatory and supporting documents.


shall be archived by the drug regulatory authority for future reference.(ll) The registration applicant shall submit a Letter of Authorizafion issued by the registrant ofimported medical devices to explicitly indicate the agreement on the use of the original registrationapplication dossiers of the imported medical devices by the registration applicant for domestic registrationapplication and production. The Letter of Authorization shall be notarized by the Notary Office where theregistrant ofthe imported medical devices is located.


III. Registration System Verification Requirements

The registration applicant shall promise that the main raw materials and the main production processwill not change, provide the self inspection report that the domestic production quality management systemof the product complies with the Good Manufacturing Practice for Medical Devices and comparison reportof overseas and domestic quality management systems.


In accordance with the medical device registration quality management system verification proceduresthe drug regulatory authorities shall conduct verilication of domestic registration applicants, and at thesame time focus on the substantive equivalence of domestic and foreign quality management systems inproduct design and development.


If there is a difference between the domestic produets to be applied for registration and the qualitymanagement system of the imported medical devices, the registration applicant shall explain in detail.promise that the relevant difierences will not cause changes in the registration items, and at the same time.make risk analysis, clarify the main risk points and control measures, and ensure the safety, efectivenessand controllable quality of the products.



加入收藏
上一篇:喜报|我司又助力1个三类器械品种顺利过评获批!
下一篇:37种医疗器械临床试验设计系列
返回列表

随便看看

  • 爱美客A型肉毒素「Hutox」申报获NMPA受理
  • 电动吻合器临床研究技术研讨会
  • 西格玛医学助力杭州柳叶刀膝关节置换手术导航定位系统获得NMPA器械注册证
  • 祝贺!我国神经外科手术材料研发获重大进展 已进入临床试验
  • 西格玛医学助力霆升科技创新一次性使用心腔内超声诊断导管获批NMPA三类注册证
  • 一文读懂胶原蛋白植入剂及鼻唇沟临床试验设计
  • 器械注册一起学12】医用妇科凝胶
  • 首款“中美双报双批”国产髋关节置换手术机器人获得三类创新医疗器械注册证
  • 祝贺!第三款“童颜针”AestheFill正式获批上市
  • 创伤骨科机器人临床试验技术研讨会

医械资源推荐

  • 质子/碳离子治疗系统技术审查指导原则

β-随机化系统

sigma培训系统

临床数据管理

贝塔临床试验管理

合作担当 正直诚信 专业精益求精 服务永无止境

立即联系我们
www.sigma-stat.com

南京市鼓楼区汉中路180号星汉大厦20楼

15366102788 / 025-86210646

  • 解决方案 器械临床试验 注册人制度 医学监查 质量管理体系 注册服务 法规事务 器械SMO 第三方稽查 数据管理 生物统计 国际注册
  • 医械资源 法律法规 指导原则 标准体系 行业规范 知识问答
  • 新闻资讯 公司动态 行业资讯 媒体报道 西格洞察
  • 关于我们 公司简介 公司荣誉 公司文化 公司优势
  • 联系我们 加入我们 商务合作
一对一服务 西格玛数据库

© 2022-2032 版权归南京西格玛医学技术股份有限公司所有

苏ICP备19023443号

互联网药品信息服务资格证书编号:(苏)-非经营性-2021-0108